AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 126.71 |
Market Cap | 13.45B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.86 |
PE Ratio (ttm) | -147.49 |
Forward PE | n/a |
Analyst | Buy |
Ask | 126.97 |
Volume | 15,775,357 |
Avg. Volume (20D) | 1,202,206 |
Open | 127.20 |
Previous Close | 127.19 |
Day's Range | 126.84 - 127.45 |
52-Week Range | 62.78 - 128.00 |
Beta | undefined |
About ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as ...
Analyst Forecast
According to 13 analyst ratings, the average rating for ITCI stock is "Buy." The 12-month stock price forecast is $100, which is a decrease of -21.16% from the latest price.
Next Earnings Release
Analysts project revenue of $193.96M, reflecting a 46.83% YoY growth and earnings per share of -0.11, making a -63.33% decrease YoY.
1 day ago · https://thefly.com
Intra-Cellular just downgraded at Morgan Stanley, here's whyIntra-Cellular +32.2 (+33.94%) Johnson & Johnson +1.38 (+0.97%)
2 days ago · proactiveinvestors.co.uk
Johnson & Johnson eyes $10bn acquisition of Intra-Cellular TherapiesJohnson & Johnson (NYSE:JNJ) is reportedly in talks to acquire neuroscience-focused biotech firm Intra-Cellular Therapies for $10bn. If completed, the deal would mark the largest biotech acquisition s...
2 months ago · seekingalpha.com
Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call TranscriptIntra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder,...